Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-820836 rollover safety study in treatment-resistant major depression
2010-024371-12Phase 2Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of liafensine in major depressive disorder (MDD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change from baseline in blood pressure through 54 weeks. Started Jun 2011; status: suspended.
02
Drugs
liafensine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-024371-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024371-12.